Merus N.V.

NasdaqGM:MRUS 주식 보고서

시가총액: US$3.5b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Merus 미래 성장

Future 기준 확인 2/6

Merus (는) 각각 연간 22.1% 및 49.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 27.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -29.1% 로 예상됩니다.

주요 정보

22.6%

수익 성장률

28.2%

EPS 성장률

Biotechs 수익 성장24.1%
매출 성장률49.6%
향후 자기자본 수익률-29.1%
애널리스트 커버리지

Good

마지막 업데이트01 Jul 2024

최근 미래 성장 업데이트

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12
Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recent updates

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12
Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

May 10
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 01
Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Jan 23

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Jan 14
Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20
Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08
Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14
Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03
New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25
We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28
Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus posts positive efficacy data from early-stage zenocutuzumab cancer study

Jun 04

수익 및 매출 성장 예측

NasdaqGM:MRUS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026108-212-154-20011
12/31/202554-220-188-18013
12/31/202441-175-171-15613
3/31/202438-150-150-150N/A
12/31/202344-155-146-142N/A
9/30/202346-177-142-136N/A
6/30/202341-178-159-150N/A
3/31/202343-152-151-140N/A
12/31/202242-131-158-150N/A
9/30/202246-64-157-151N/A
6/30/202253-54-137-133N/A
3/31/202252-76-126-125N/A
12/31/202149-67-60-60N/A
9/30/202143-80-53-52N/A
6/30/202138-89-42-41N/A
3/31/202132-79-37-35N/A
12/31/202030-86-81-80N/A
9/30/202029-83-76-75N/A
6/30/202028-69-80-78N/A
3/31/202029-65-77-75N/A
12/31/201931-55-66-63N/A
9/30/201937-32-61-56N/A
6/30/201935-34-63-58N/A
3/31/201936-26-50-45N/A
12/31/201838-28-50-46N/A
9/30/201834-41-48-46N/A
6/30/201833-45-44-43N/A
3/31/201834-66-55-54N/A
12/31/201726-78N/A-45N/A
9/30/201718-100N/A-44N/A
6/30/201712-87N/A-33N/A
3/31/20176-66N/A-27N/A
12/31/20163-50N/A-27N/A
9/30/20164-25N/A-27N/A
6/30/20163-26N/A-30N/A
3/31/20163-27N/A-29N/A
12/31/20152-25N/A-25N/A
9/30/20152-25N/A-23N/A
6/30/20152-23N/A-19N/A
3/31/20151-20N/A-17N/A
12/31/20142-21N/A-18N/A
12/31/20131-14N/A-10N/A

애널리스트 미래 성장 예측

수입 대 저축률: MRUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MRUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MRUS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MRUS 의 수익(연간 49.6% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MRUS 의 수익(연간 49.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MRUS (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견